Free Newsletter
Examining your relationship with CROs
Today we welcome another regular contributor to our Industry Voices column. Stephanie Wells is the Corporate Senior Vice President, Marketing and Chief Marketing Officer at Charles River Laboratories, a U.S.-based CRO with more than 9,000 employees worldwide. Wells has over twenty-five years of healthcare business experience, and has previously worked at Prior Ortho-Clinical Diagnostics (a Johnson & Johnson company) and Bayer Diagnostics.
Wells' executive position at a leading CRO has given her insight into how biotech and pharmaceutical companies can maximize their relationships with CROs. This changing healthcare landscape, she says, is the driving force behind a collaborative evolution within the industry, transforming traditional pharma-CRO relationships. To get Well's advice, scroll down or click here to read her article on getting the most from your CRO. - Maureen
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: